Biogen (BIIB) to Report Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS at American Neurological Association Annual Meeting

Biogen Inc. (Nasdaq: BIIB) today announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense oligonucleotide (ASO) drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), will be presented at the upcoming American Neurological Association (ANA) 2021 virtual meeting, October 17-19, 2021.

You May Also Be Interested In

• Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
• Exelixis colorectal cancer trial misses one of two survival goals
• FDA grants breakthrough therapy status to Praxis drug for rare epilepsy